Product Name

  • Name

    2H-1,4-BENZODIAZEPIN-2-ONE, 7-CHLORO-1-(CYCLOPROPYLMETHYL)-5-(2-FLUOROPHENYL)-1,3-DIHYDRO-

  • EINECS
  • CAS No. 25967-29-7
  • Article Data6
  • CAS DataBase
  • Density 1.37g/cm3
  • Solubility
  • Melting Point 118-122°
  • Formula C19H16ClFN2O
  • Boiling Point 539.3 °C at 760 mmHg
  • Molecular Weight 342.8
  • Flash Point 279.9 °C
  • Transport Information
  • Appearance
  • Safety
  • Risk Codes
  • Molecular Structure Molecular Structure of 25967-29-7 (2H-1,4-BENZODIAZEPIN-2-ONE, 7-CHLORO-1-(CYCLOPROPYLMETHYL)-5-(2-FLUOROPHENYL)-1,3-DIHYDRO-)
  • Hazard Symbols
  • Synonyms 2H-1,4-Benzodiazepin-2-one,7-chloro-1-(cyclopropylmethyl)-5-(o-fluorophenyl)-1,3-dihydro- (8CI);1-Cyclopropylmethyl-5-(o-fluorophenyl)-7-chloro-1,3-dihydro-2H-1,4-benzodiazepine-2-one;Flutoprazepam;ID 1937;KB 509;Restar;Restas;
  • PSA 32.67000
  • LogP 3.57370

Flutoprazepam Specification

 The Flutoprazepam ,its cas register number is 25967-29-7. IUPAC name about this chemicals is 7-chloro-1-(cyclopropylmethyl)-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one . Following are the physical and chemical properties about it: (1)Index of Refraction: 1.661 ; (2)Molar Refractivity: 92.24 cm3 ; (3)Molar Volume: 249.3 cm3 ; (4)Surface Tension: 48.2 dyne/cm ; (5) Enthalpy of Vaporization: 81.66 kJ/mol ; (6)Vapour Pressure: 1.07E-11 mmHg at 25°C . Classification code about it are Drug / Therapeutic Agent and Reproductive Effect .

The Flutoprazepam is a drug which is a benzodiazepine derivative. this chemicals was invented in Japan in 1972, and its medical use remains mostly confined to that country. Its muscle relaxant properties are approximately equivalent to those of diazepam - however, it has more powerful sedative, hypnotic, anxiolytic and anticonvulsant effects and is around four times more potent by weight compared to diazepam. It is longer acting than diazepam due to its long-acting active metabolites, which contribute significantly to its effects. Also it can be typically used for the treatment of severe insomnia and may also be used for treating stomach ulcers.

Abuse of benzodiazepines in Japan is extremely common, flutoprazepam is being one of the most commonly abused, along with the benzodiazepines of abuse nimetazepam, temazepam and triazolam.This chemicals is currently a Schedule IV drug under the international Convention on Psychotropic Substances of 1971. In Singapore, it is a Class C-Schedule II drug under the Misuse of Drugs Act. Also in Hong Kong, flutoprazepam is regulated under Schedule 2 of Hong Kong's Chapter 134 Dangerous Drugs Ordinance. It may be prescribed for the treatment of insomnia by a registered medical doctor. The penalty for trafficking or manufacturing the substance is a $100,000 (HKD) fine and possibly a short imprisonment (1-2 years). Possession of the substance for consumption without valid prescription from a registered medical doctor is illegal and punishable with a $50,000 (HKD) fine.

This chemicals can be described computed from structure: 
1) Canonical SMILES: C1CC1CN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4F
2) InChI: InChI=1S/C19H16ClFN2O/c20-13-7-8-17-15(9-13)19(14-3-1-2-4-16(14)21)22-10-18(24)23(17)11-12-5-6-12/h1-4,7-9,12H,5-6,10-11H2
3) InChIKey: OFVXPDXXVSGEPX-UHFFFAOYSA-N

The most important thing about Flutoprazepam is the toxicity, following is the form:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LD50 oral > 10gm/kg (10000mg/kg) SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

GASTROINTESTINAL: NAUSEA OR VOMITING
Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 1005, 1980.
monkey LD50 oral > 4gm/kg (4000mg/kg) GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS

GASTROINTESTINAL: NAUSEA OR VOMITING
Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 1005, 1980.
mouse LD50 intraperitoneal 2110mg/kg (2110mg/kg) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

BEHAVIORAL: ATAXIA
Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 1055, 1980.
mouse LD50 oral 2430mg/kg (2430mg/kg) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

BEHAVIORAL: ATAXIA
Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 1055, 1980.
mouse LD50 subcutaneous > 5gm/kg (5000mg/kg) BEHAVIORAL: MUSCLE WEAKNESS

BEHAVIORAL: ATAXIA
Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 1005, 1980.
rabbit LD50 oral 1gm/kg (1000mg/kg) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

BEHAVIORAL: ATAXIA
Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 1055, 1980.
rat LD50 intraperitoneal 2230mg/kg (2230mg/kg) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

BEHAVIORAL: ATAXIA
Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 1055, 1980.
rat LD50 oral 10060mg/kg (10060mg/kg) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

BEHAVIORAL: ATAXIA
Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 1055, 1980.
rat LD50 subcutaneous > 5gm/kg (5000mg/kg) BEHAVIORAL: MUSCLE WEAKNESS

BEHAVIORAL: ATAXIA
Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 1005, 1980.

 

Post buying leads

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View